Lunai Bioworks (RENB) Competitors $1.54 +0.28 (+21.72%) Closing price 09/30/2025Extended Trading$1.54 0.00 (0.00%) As of 09/30/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RENB vs. ABUS, MNMD, KOD, DNA, PHAT, SANA, RZLT, SEPN, BCAX, and XNCRShould you be buying Lunai Bioworks stock or one of its competitors? The main competitors of Lunai Bioworks include Arbutus Biopharma (ABUS), Mind Medicine (MindMed) (MNMD), Kodiak Sciences (KOD), Ginkgo Bioworks (DNA), Phathom Pharmaceuticals (PHAT), Sana Biotechnology (SANA), Rezolute (RZLT), Septerna (SEPN), Bicara Therapeutics (BCAX), and Xencor (XNCR). These companies are all part of the "pharmaceutical products" industry. Lunai Bioworks vs. Its Competitors Arbutus Biopharma Mind Medicine (MindMed) Kodiak Sciences Ginkgo Bioworks Phathom Pharmaceuticals Sana Biotechnology Rezolute Septerna Bicara Therapeutics Xencor Arbutus Biopharma (NASDAQ:ABUS) and Lunai Bioworks (NASDAQ:RENB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability. Do insiders and institutionals believe in ABUS or RENB? 43.8% of Arbutus Biopharma shares are held by institutional investors. Comparatively, 71.4% of Lunai Bioworks shares are held by institutional investors. 20.3% of Arbutus Biopharma shares are held by company insiders. Comparatively, 0.5% of Lunai Bioworks shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts prefer ABUS or RENB? Arbutus Biopharma currently has a consensus target price of $5.00, indicating a potential upside of 21.65%. Given Arbutus Biopharma's stronger consensus rating and higher possible upside, research analysts plainly believe Arbutus Biopharma is more favorable than Lunai Bioworks.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arbutus Biopharma 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has better valuation and earnings, ABUS or RENB? Arbutus Biopharma has higher revenue and earnings than Lunai Bioworks. Arbutus Biopharma is trading at a lower price-to-earnings ratio than Lunai Bioworks, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArbutus Biopharma$15.42M51.11-$69.92M-$0.29-14.17Lunai BioworksN/AN/A-$88.43M-$0.77-2.00 Which has more volatility and risk, ABUS or RENB? Arbutus Biopharma has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Comparatively, Lunai Bioworks has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500. Is ABUS or RENB more profitable? Lunai Bioworks has a net margin of 0.00% compared to Arbutus Biopharma's net margin of -352.24%. Arbutus Biopharma's return on equity of -59.28% beat Lunai Bioworks' return on equity.Company Net Margins Return on Equity Return on Assets Arbutus Biopharma-352.24% -59.28% -44.11% Lunai Bioworks N/A -60.38%-47.04% Does the media prefer ABUS or RENB? In the previous week, Arbutus Biopharma had 5 more articles in the media than Lunai Bioworks. MarketBeat recorded 6 mentions for Arbutus Biopharma and 1 mentions for Lunai Bioworks. Lunai Bioworks' average media sentiment score of 1.91 beat Arbutus Biopharma's score of 0.31 indicating that Lunai Bioworks is being referred to more favorably in the news media. Company Overall Sentiment Arbutus Biopharma Neutral Lunai Bioworks Very Positive SummaryArbutus Biopharma beats Lunai Bioworks on 11 of the 15 factors compared between the two stocks. Get Lunai Bioworks News Delivered to You Automatically Sign up to receive the latest news and ratings for RENB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RENB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RENB vs. The Competition Export to ExcelMetricLunai BioworksMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$250.24M$3.32B$6.01B$10.23BDividend YieldN/A2.29%5.66%4.69%P/E Ratio-2.0022.1185.3526.57Price / SalesN/A416.63582.95179.01Price / CashN/A47.1938.3262.20Price / Book1.7310.2112.726.53Net Income-$88.43M-$52.40M$3.30B$275.87M7 Day PerformanceN/A0.90%1.07%-1.40%1 Month Performance-25.52%12.36%7.61%5.16%1 Year Performance-65.01%30.17%79.71%31.51% Lunai Bioworks Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RENBLunai Bioworks0.7165 of 5 stars$1.54+21.7%N/A-63.3%$250.24MN/A-2.0020Positive NewsGap DownABUSArbutus Biopharma1.8722 of 5 stars$4.49+0.6%$5.00+11.5%+13.6%$859.78M$6.17M-15.4790News CoverageNegative NewsAnalyst ForecastMNMDMind Medicine (MindMed)2.3828 of 5 stars$11.30-6.2%$26.50+134.6%+138.1%$859.51MN/A-7.3840Analyst ForecastKODKodiak Sciences3.621 of 5 stars$16.32+3.2%$13.00-20.4%+417.2%$858.33MN/A-4.2890Analyst ForecastAnalyst RevisionDNAGinkgo Bioworks1.2942 of 5 stars$14.25+7.7%$9.00-36.8%+91.9%$845.32M$227.04M-2.44640News CoverageAnalyst ForecastPHATPhathom Pharmaceuticals2.357 of 5 stars$11.78+4.0%$17.50+48.6%-26.1%$835.67M$55.25M-2.49110Analyst ForecastSANASana Biotechnology2.9016 of 5 stars$3.50-1.3%$7.50+114.6%+11.5%$831.15MN/A-3.30380News CoverageAnalyst ForecastRZLTRezolute2.77 of 5 stars$9.23-0.6%$14.50+57.0%+87.9%$830.00MN/A-9.4240Analyst ForecastSEPNSepterna1.1492 of 5 stars$18.59+2.4%$26.75+43.9%N/A$828.52M$1.08M-1.84N/ANews CoverageAnalyst ForecastGap DownBCAXBicara Therapeutics2.1655 of 5 stars$15.23+9.8%$32.25+111.8%-10.0%$821.35MN/A-4.7532News CoverageInsider TradeXNCRXencor3.7646 of 5 stars$11.46-0.8%$22.25+94.2%-33.5%$816.97M$110.49M-4.77280Analyst UpgradeAnalyst Revision Related Companies and Tools Related Companies Arbutus Biopharma Alternatives Mind Medicine (MindMed) Alternatives Kodiak Sciences Alternatives Ginkgo Bioworks Alternatives Phathom Pharmaceuticals Alternatives Sana Biotechnology Alternatives Rezolute Alternatives Septerna Alternatives Bicara Therapeutics Alternatives Xencor Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RENB) was last updated on 10/10/2025 by MarketBeat.com Staff From Our PartnersThe best AI stock you aren’t watching (but Elon is)Elon Musk's AI empire is already being built... not in the spotlight, but in the background. One public cou...Behind the Markets | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredU.S. Government Sparking Crypto RallyAltcoin ETFs could surge prices (do this now) My "Crypto Bull Run Millionaire Blueprint" breaks down exactl...Crypto 101 Media | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredBig Oil Firm Stakes $1 Billion in Startup That Could Kill Big OilOn September 22, the unthinkable happened... One of the world's biggest oil producers poured $1 billion int...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lunai Bioworks Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lunai Bioworks With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
